Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial - discussion

9 April 2024 (11:17 - 11:21)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Tatjana Potpara

School of Medicine, Belgrade University, Belgrade (Serbia)

9 More presentations in this session

Presentation thumbnail

Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease

Doctor E. Pisano (Lecce, IT)

Presentation thumbnail

Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease - discussion

Doctor N. Varma (Cleveland, US)

Presentation thumbnail

Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.

Doctor J. Nikorowitsch (Hamburg, DE)

Presentation thumbnail

Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial. - discussion

Doctor S. Al-Khatib (Durham, US)

Presentation thumbnail

Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial

Doctor W. McIntyre (Hamilton, CA)

Access the full session

Session thumbnail

Late-Breaking Science: devices

The Event

Event poster

EHRA 2024

9 April 2024 11:17 CET

You may be interested in

Congress Presentation

What is the evidence for anticoagulation in subclinical atrial fibrillation detection?

Congress Presentation

Reducing stroke risk in patients with atrial high-rate episodes (AHRE)

Congress Session

Subclinical and device-detected atrial fibrillation: fact and fiction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources